Variolation

Part of Vaccines

The historical practice of deliberately inoculating individuals with smallpox material to produce mild protective infection.

Why This Matters

Variolation was not a vaccine. It was the deliberate infection of healthy individuals with actual smallpox material — specifically chosen from mild cases — in the hope that they would develop a milder form of the disease than if they encountered smallpox naturally, and would thereafter be immune. It predates Jenner’s cowpox vaccination by at least a century and was practiced across Asia, Africa, and the Middle East long before European medicine adopted it.

Variolation killed approximately 1-2% of those variolated — compared to 20-30% mortality from natural smallpox. This unfavorable comparison to vaccination makes variolation look primitive. But in the context of endemic smallpox, it was rational: a 1-2% risk was vastly preferable to the 20-30% risk of natural infection, especially for children.

Understanding variolation matters in a rebuilding context for two reasons. First, the historical record provides detailed practical knowledge about how protective immunity was achieved against a major killer before laboratory science existed. Second, if the vaccination principle is understood, variolation represents a last-resort fallback when no attenuated alternative exists — one to be used only with full understanding of its risks.

Historical Practice

China and Central Asia (10th-12th century onward): The earliest documented variolation practice was inoculation of dried smallpox crust material. Two main methods:

• Nasal insufflation: dried crusts ground to powder and blown into the nose with a small pipe. The powder was derived from mild cases and often aged for several weeks (which reduced the virulence of the material).
• Skin inoculation: material from fresh vesicles applied to a small skin abrasion, usually on the arm.

Chinese practitioners distinguished between material from mild cases (safer) and severe cases (more dangerous), and observed that aged material was safer than fresh. These were empirical attenuation methods — not understood mechanistically but effective in practice.

Ottoman Empire and Africa: Lady Mary Wortley Montagu observed Turkish variolation in 1717 and introduced the practice to England. The Turkish method used a needle to scratch fresh pus from a mild smallpox pustule into the arm. African practices used similar inoculation methods that had been in place for generations, independent of Asian practice.

European adoption (1720s-1790s): After initial resistance from the medical establishment, variolation was tested systematically in England (including on prisoners and orphans) and shown to reduce mortality from smallpox. It was adopted by royal courts and eventually by physicians. Benjamin Franklin, who lost a son to smallpox, became a strong advocate after the fact.

Limitations that drove the search for vaccination:

• 1-2% mortality — unacceptable when a safe alternative became available
• Variolated individuals could infect susceptible contacts — they were genuinely infectious
• Unpredictable virulence — even mild-case material could occasionally cause severe disease
• Required constant access to active smallpox cases as source material

The Biology of Variolation

Why it mostly worked: Smallpox inoculated through skin into the arm typically produced a less severe disease than naturally acquired smallpox via the respiratory route. Natural infection enters through the respiratory tract and establishes infection in a much more vulnerable mucosal surface, with higher viral load delivered directly to the lungs and lymph. Cutaneous inoculation delivers less virus into an environment (skin) where initial replication is slower and local immune defenses have time to mount before systemic spread.

Additionally, selecting material from mild cases selected for somewhat less virulent viral strains — not a reliable selection, but statistically better than random.

The result: Most variolated individuals developed a localized pustular response at the inoculation site, mild systemic illness for 5-10 days, and then full immunity. They were protected against future smallpox encounters — the same memory-based protection as natural infection, just through a controlled less-severe initial exposure.

Practical Protocol (Historical)

Source material selection:

• Choose donor cases that have mild disease: fewer pustules, good overall condition, no confluent (merged) skin lesions
• Collect from vesicular stage (day 5-7) before pustule develops — less infectious material more virus, more antigen
• Many practitioners avoided material from secondary infections in contact cases (third or fourth generation), preferring primary cases

Material collection:

• Open vesicle with lancet or needle
• Collect fluid directly onto the point of the lancet, or into a glass capillary tube
• Use immediately (fresh material) or preserve in glycerol or by slight desiccation for transport

Preparation of recipient:

• Ideally in good general health, no active illness
• Some practitioners observed a preparatory period of light diet and rest, believing this improved outcomes (probably did not affect outcomes but established patient compliance)

Inoculation:

• Arm, usually deltoid region or inner forearm
• Make a small superficial scratch or puncture with lancet or needle — not deep, just through the epidermis
• Apply material directly to the abraded skin
• Allow to dry; cover loosely
• Do not use alcohol at site (this kills the virus)

Expected progression:

• Day 3-5: small papule at inoculation site
• Day 5-8: vesicle develops; mild fever begins
• Day 8-12: pustule at inoculation site; systemic symptoms peak (fever, malaise, axillary swelling)
• Day 12-20: recovery; pustule crusts and heals
• Patient is infectious during the vesicular/pustular phase

Isolation requirement: Variolated individuals MUST be isolated from susceptible contacts during the infectious period. Failure to isolate has caused smallpox outbreaks from variolation programs. This is one of the most important operational requirements and historically the most commonly violated.

Risk Assessment

Mortality risk of variolation (historical):

• Material from mild cases, experienced practitioners: approximately 0.5-1%
• Material from severe cases or inexperienced practitioners: 1-3%
• Natural smallpox mortality: 20-30% (major) or 1-2% (minor/alastrim)

Risk ratio: Variolation with good material is approximately 20-60× safer than unprotected exposure in an endemic environment. This justifies use when no better alternative (vaccination with cowpox or vaccinia) is available.

Secondary spread risk: Variolated individuals are infected with live smallpox virus and can transmit to susceptible contacts. Strict isolation for 3 weeks from day of inoculation is the minimum safety requirement.

Risk factors for severe variolation outcome:

• Material from severe smallpox case
• Very young infants (under 1 year)
• Immunocompromised recipients
• Pregnancy
• Overcrowded conditions with multiple susceptible contacts

When Variolation Is the Best Available Option

If smallpox or a closely related poxvirus (monkeypox) is circulating and no safer vaccine material is available:

1. Identify currently infected cases with mild presentation
2. Collect material from appropriate vesicular stage using sterile technique
3. Test material virulence in an available animal model if possible
4. Prioritize highest-risk individuals (young children, caregivers) for inoculation
5. Strict isolation of all variolated individuals for full infectious period
6. Monitor all contacts for disease during isolation period
7. Document every inoculation and outcome

Variolation should never be used when safer alternatives (vaccinia, cowpox) are available. It should be considered only as a last resort in the context of active epidemic threat, with full understanding of the risks and absolute commitment to isolation requirements.

The history of variolation shows that empirical medicine without laboratory science can achieve real protection against deadly disease. The principle — that controlled, milder exposure can provide immunity — is correct. The implementation carries risks that modern vaccination has eliminated, but those risks must be weighed against the alternative of no protection at all.

Topics covered in dedicated articles: Cowpox-Smallpox Link, Vaccination Principle